Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2010 - 2025)
Whitehawk Therapeutics' (WHWK) quarterly Cash from Financing Activities came in at $25000.0 in Q4 2025, down 52.83% year-on-year from $53000.0 in Q4 2024, and up 102.94% on a QoQ basis from -$850000.0 in Q2 2025.
Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 12 years of Cash from Financing Activities data on file, last reported at $25000.0 in Q4 2025.
- On a quarterly basis, Cash from Financing Activities fell 52.83% year-over-year to $25000.0 in Q4 2025; TTM through Mar 2026 was -$825000.0, a 100.87% decrease from a year earlier, with the FY2025 full-year figure at $94.4 million, up 72496.92% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $25000.0, up from -$850000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for WHWK reached as high as $141.7 million in Q3 2021 and fell as low as -$850000.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $17.2 million across 5 years, with a median of $61639.5 in 2021.
- On a YoY basis, Cash from Financing Activities climbed as much as 952110.0% in 2025 and fell as far as 1077.01% in 2025.
- Year by year, Cash from Financing Activities stood at $88000.0 in 2021, then tumbled by 221.59% to -$107000.0 in 2022, then jumped by 174.77% to $80000.0 in 2023, then slumped by 33.75% to $53000.0 in 2024, then tumbled by 52.83% to $25000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $25000.0 in Q4 2025, -$850000.0 in Q2 2025, and $95.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Whitehawk Therapeutics | 34.18 Mn | 34.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Jun 30, 2025 | -850,000.00 |
| Jun 30, 2025 | -850,000.00 |
| Mar 31, 2025 | 95.20 Mn |
| Mar 31, 2025 | 95.20 Mn |
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Jun 30, 2023 | 313,000.00 |
| Jun 30, 2023 | 313,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Mar 31, 2023 | 8,000.00 |